Notícias e Atividades da Mineralys Therapeutics

Mineralys Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Mineralys Therapeutics é uma empresa listada sob o símbolo MLYS (US).

Veja o organograma con seus 19 executivos principais

Biografias mais buscadas da Mineralys Therapeutics

• Jon Congleton, Chief Executive Officer
• BT Slingsby, Director
• Daphne Karydas, Director

Recentes movimentos de executivos em Mineralys Therapeutics

• Stephen Djedjos, Senior Vice President, Clinical Development, deixou a Companhia  (Notícia publicada em 24 de janeiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Mineralys Therapeutics.

Mineralys Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Mineralys Therapeutics

• Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
• Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
• Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
• Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
• Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
• Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
• Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
• Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
• Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
• View more press releases Close

Redes sociais sobre Mineralys Therapeutics

• Mineralys Therapeutics na Wikipedia, Google News e Yahoo Finance
• Mineralys Therapeutics na LinkedIn, Twitter e YouTube